Promimic (PRO) investor relations material

Executive summary

• Net sales for 2025 reached 44.4 MSEK, up 1% year-over-year, with Q4 sales at 11.5 MSEK, down 9% from Q4 2024.

• Operating loss for the year improved to -7.7 MSEK from -8.3 MSEK, and net loss after tax was -8.8 MSEK, a reduction from -12.6 MSEK in 2024.

• Six new customer agreements were signed, marking a record for the company and laying the foundation for future growth.

• Over 2.6 million implants with HAnano Surface are now in clinical use, with 25% of these sold in the last year.

• Key milestones included strategic partnerships, FDA approvals for customer products, and expansion of US operations.

Financial highlights

• Total operating income for 2025 was 52.7 MSEK, up 7% year-over-year.

• EBITDA for the year was -2.9 MSEK, compared to -3.2 MSEK in 2024.

• Cash flow for the year was -13.0 MSEK, with cash and equivalents at year-end of 20.6 MSEK, down from 35.8 MSEK.

• Equity ratio remained strong at 78%.

• Earnings per share for 2025 were -0.46 SEK, improved from -0.67 SEK in 2024.

Outlook and guidance

• Targeting a CAGR above 25% at constant currency, with an EBITDA margin goal above 40%.

• Investments in US operations are expected to decrease, with focus shifting to capitalizing on expanded capacity.

• Growth expected from new customer agreements and increased clinical adoption of HAnano Surface.